Available Trials

• Bladder
• Breast
• Cholangiocarcinoma
• Colorectal
• Endometrial
• Gynecological/Ovarian
• Hematology
• Leukemia
• Lung - Non-Small Cell Lung
• Lymphoma
• Multiple Myeloma
• Myelomas
• Pancreas
• PNH
• Prostate
• Solid Tumor
• Urothelial

Bladder

• USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)

  Available at: Arlington Heights

  ---

Breast

• HER2+ Breast Trial USOR 19054: A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable, Locally-Advanced, or Metastatic HER2+ Breast Cancer. (HER2CLIMB-02)(SGNTUC-016)

  Available at: Arlington Heights, Niles

  ---

Cholangiocarcinoma

• USOR 18264: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations. The PROOF Trial (QBGJ398-301)

  Available at: Arlington Heights, Niles

  ---

Colorectal

• USOR 20157 PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer (FRNM-004)

  Available at: Arlington Heights

  ---

• USOR 18261: A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. (CA2098HW)

  Available at: Arlington Heights, Niles

  ---

Endometrial

• USOR 19221: A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer. (DUO-E) D9311C00001; GOG-3041; ENGOT-EN10

  Available at: Arlington Heights, Niles

  ---

Gynecological/Ovarian

• USOR 19200 A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. (IMGN853-0416)(MIRASOL)

  Available at: Arlington Heights, Niles

  ---

Hematology

• USOR 18130 INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309.)

  Available at: Niles

  ---

Leukemia

• USOR 19205 ULTRA-V: A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

  Available at: Arlington Heights, Niles

  ---

Lung - Non-Small Cell Lung

• NOW OPEN USOR 20137: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer, Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03) (GO41854)

  Available at: Arlington Heights, Niles

  ---

• USOR 19018: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) Mirati 516-005

  Available at: Arlington Heights, Niles

  ---

• USOR 19192 A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)

  Available at: Arlington Heights, Niles

  ---

• USOR 19044: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer. (D9103C00001)(PACIFIC-4/RTOG-3515)

  Available at: Niles

  ---

Lymphoma

• NOW OPEN: USOR 20219 A Dual-Cohort, Open-Label, Phase 2, Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-Cell Lymphoma (PTCL) with Less Than 10% CD30 Expression. (SGN35-032)

  Available at: Niles

  ---

• USOR 20144: A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multi-Center, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(SGN35-031)

  Available at: Arlington Heights, Niles

  ---

• USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

  Available at: Niles, Arlington Heights

  ---

• USOR 11282 A Phase 2, Open-Label Study, of Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above.(SGN35-015)

  Available at: Niles

  ---

Multiple Myeloma

• USOR 19247 A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

  Available at: Arlington Heights, Niles

  ---

Myelomas

• USOR 18230 DREAMM 7: A Multicenter, Open- Label, Randomized, Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma (207503.)

  Available at: Arlington Heights, Niles

  ---

Pancreas

• USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

  Available at: Niles, Arlington Heights

  ---

PNH

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles, Arlington Heights

  ---

Prostate

• NOW OPEN USOR 19191 A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo, In Combination With Docetaxel, in Men with Metastatic, Castration-Resistant, Prostate Cancer. (CA209-7DX)

  Available at: Arlington Heights, Niles

  ---

Solid Tumor

• USOR 19151 A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Sold Tumors with KRAS G12C Mutation (849-001) STAR

  Available at: Niles

  ---

• USOR 19079 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)(INCB54828-207)

  Available at: Arlington Heights, Niles

  ---

Urothelial

• USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)

  Available at: Arlington Heights

  ---